Evidence map›Paper›PMID 38543058›Full record

ReviewPharmaceuticals (Basel, Switzerland)2024

Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review.

Andrei Suponin, Pavel Zhelnov, Artem Potanin, Andrey Chekalov, Aleksandr Lomazov, Kseniia Vladimirova, Kirill Lepik, Albert Muslimov

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Andrei SuponinRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.
Pavel ZhelnovIndependent Researcher, Mexico City 07780, Mexico.ORCID 0000-0003-2767-5123
Artem PotaninRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.
Andrey ChekalovRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.
Aleksandr LomazovRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.
Kseniia VladimirovaRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.
Kirill LepikRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.
Albert MuslimovRM Gorbacheva Research Institute, Pavlov University, L'va Tolstogo 6-8, 197022 St. Petersburg, Russia.ORCID 0000-0001-5736-2764
First Pavlov State Medical University of St. Petersburg · RUMSD (Mexico) · MXPeter the Great St. Petersburg Polytechnic University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: We aimed to estimate the pooled effectiveness and safety of vaccination in follicular lymphoma (FL) and discuss implications for immunotherapy development. (2) Methods: We included randomized trials (RCTs) of therapeutic vaccines in patients with FL. Progression-free survival (PFS) was the primary outcome. We searched databases (PubMed, Embase, Scopus, Web of Science Core, medRxiv) and registries (PROSPERO, CENTRAL, ClinicalTrials.gov, EuCTR, WHO ICTRP) and conducted online, citation, and manual searches. We assessed risks of bias across outcomes using RoB 2.0 and across studies using ROB-ME and a contour-enhanced funnel plot. (3) Results: Three RCTs were included (813 patients, both previously treated and untreated). Patients with a complete or partial response after chemotherapy were randomized to either a patient-specific recombinant idiotype keyhole limpet hemocyanin (Id-KLH) vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) or placebo immunotherapy (KLH + GM-CSF). Meta-analyses showed that PFS was worse with the vaccine, but not significantly: hazard ratio, 1.09 (95% CI 0.91-1.30). The GRADE certainty of evidence was moderate. Adverse event data were mixed. (4) Conclusions: We are moderately certain that Id-KLH results in little to no difference in PFS in FL. (5) Funding: Russian Science Foundation grant #22-25-00516. (6) Registration: PROSPERO CRD42023457528.

Indexed as

immunizationindividual participant data reconstructionnon-Hodgkin indolent lymphoma

Identifiers

PMID38543058
PMCPMC10974604
OpenAlexW4391994614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.